ANN ARBOR, Mich. & PHILADELPHIA--(BUSINESS WIRE)--May 15, 2007--SensiGen LLC, a biotechnology company focused on developing proprietary gene-based molecular diagnostics announced today that Ann Arbor SPARK, the driving force in establishing the Ann Arbor region as a destination for business expansion, retention, and location, has approved a $250,000 investment in SensiGen from the Michigan Pre-Seed Capital Fund.

The funds will be used to help SensiGen establish a new research laboratory in Ann Arbor and to accelerate development of the Company's revolutionary AttoSense(TM) molecular diagnostic technology.

"We are extremely grateful and honored to have Ann Arbor SPARK as an investor," said Shawn M. Marcell, President and CEO of SensiGen. "This is yet another example of the outstanding support and resources available to start-up companies in the Ann Arbor area." SensiGen's breakthrough molecular diagnostic technology was developed by Dr. David Kurnit in his laboratory at the University of Michigan. Since its founding in 2002, the Company has raised more than $3.25 million in pre-seed investment from the Michigan Economic Development Corporation and a variety of angel investors in addition to the investment from SPARK.

"SensiGen has incredible technology and a solid management team, and is now well positioned for rapid growth as they commercialize several exciting new medical diagnostics that will save lives and improve health care for millions of people," said Skip Simms, Ann Arbor SPARK's Pre-Seed Fund Administrator. "This is an excellent example of how public-private partnerships like SPARK can indeed have an impact on generating growth and jobs. This investment will be returned to our community many times over in the months and years ahead."

About SensiGen, LLC: SensiGen is a development stage biotechnology company focused on gene-based molecular diagnostics. Founded in 2002, the Company's mission is to develop advanced technologies to enable early detection of diseases, thereby improving the standard of care and reducing overall health costs. Current products in development include advanced tests for early detection of human papillomavirus (HPV), the primary cause of cervical cancer, chronic kidney disease (CKD), Crohn's disease, Lupus and others. SensiGen's proprietary molecular diagnostic assays offer dramatic improvements over current methods, and can potentially provide significant value to patients, care givers, and insurers alike.

About Ann Arbor SPARK: Representing all communities in Washtenaw County, Ann Arbor SPARK, a non-profit organization, is the driving force in establishing the Ann Arbor region as a destination for business expansion, retention, and location by identifying and meeting the needs of business at every stage, from startups to large organizations. Ann Arbor SPARK collaborates with business, academic, government, and community investor partners including the University of Michigan, Eastern Michigan University, the Herbert and Grace Dow Foundation, Pfizer, Washtenaw County, the City of Ann Arbor, the Bank of Ann Arbor, the Michigan Economic Development Corporation and the LDFA. For more information, please call (734) 761-9317 or visit www.AnnArborSPARK.org.